ES2570205T3 - Sistema terapéutico transdérmico con pequeña tendencia a la cristalización espontánea - Google Patents

Sistema terapéutico transdérmico con pequeña tendencia a la cristalización espontánea

Info

Publication number
ES2570205T3
ES2570205T3 ES12810316T ES12810316T ES2570205T3 ES 2570205 T3 ES2570205 T3 ES 2570205T3 ES 12810316 T ES12810316 T ES 12810316T ES 12810316 T ES12810316 T ES 12810316T ES 2570205 T3 ES2570205 T3 ES 2570205T3
Authority
ES
Spain
Prior art keywords
transdermal therapeutic
layers
matrix
melting point
therapeutic system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12810316T
Other languages
English (en)
Inventor
Horst Dzekan
Hans-Rainer Hoffmann
Michael Horstmann
Walter Müller
Sandra Wiedersberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
LTS Lohmann Therapie Systeme AG
Original Assignee
UCB Pharma GmbH
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47505017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2570205(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Pharma GmbH, LTS Lohmann Therapie Systeme AG filed Critical UCB Pharma GmbH
Application granted granted Critical
Publication of ES2570205T3 publication Critical patent/ES2570205T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Abstract

Sistema terapéutico transdérmico (TTS) que comprende una capa posterior impermeable a la sustancia activa, una matriz constituida por una, dos o más capas y una capa de protección desprendible, caracterizado por que la capa o capas de matriz o al menos una de las capas de matriz comprenden al menos un pegamento autoadhesivo, al menos un medicamento y partículas de polivinilpirrolidona transversalmente reticulada, y durante la fabricación de la capa o capas de matriz que contienen medicamento y/o el revestimiento de la capa posterior impermeable a la sustancia activa del sistema terapéutico transdérmico se ha realizado un tratamiento a temperatura en el que la temperatura estaba por encima del punto de fusión o el intervalo de punto de fusión de la modificación estable del medicamento o medicamentos, preferiblemente al menos 10ºC por encima del punto de fusión o del intervalo de fusión de dicha modificación estable, consistiendo el pegamento autoadhesivo en un pegamento autoadhesivo fusible.
ES12810316T 2011-12-30 2012-12-28 Sistema terapéutico transdérmico con pequeña tendencia a la cristalización espontánea Active ES2570205T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011090178A DE102011090178A1 (de) 2011-12-30 2011-12-30 Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
PCT/EP2012/077046 WO2013098390A1 (de) 2011-12-30 2012-12-28 Transdermales therapeutisches system mit geringer neigung zur spontankristallisation

Publications (1)

Publication Number Publication Date
ES2570205T3 true ES2570205T3 (es) 2016-05-17

Family

ID=47505017

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12810316T Active ES2570205T3 (es) 2011-12-30 2012-12-28 Sistema terapéutico transdérmico con pequeña tendencia a la cristalización espontánea

Country Status (10)

Country Link
US (2) US20140378917A1 (es)
EP (1) EP2797588B1 (es)
JP (1) JP6335790B2 (es)
CN (2) CN110251490A (es)
BR (1) BR112014016176B1 (es)
CA (1) CA2861782C (es)
DE (1) DE102011090178A1 (es)
ES (1) ES2570205T3 (es)
HK (1) HK1202430A1 (es)
WO (1) WO2013098390A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU180500U1 (ru) * 2017-08-01 2018-06-14 Игорь Александрович Зябрев Технологическая головка для лазерной аддитивной технологии
US11607394B2 (en) 2017-12-19 2023-03-21 Hisamitsu Pharmaceutical Co., Inc. Rotigotine-containing patch
CN108358911A (zh) * 2018-04-19 2018-08-03 安徽德信佳生物医药有限公司 一种磁性诱导结晶分离东莨菪碱的方法
US20220117934A1 (en) 2019-02-15 2022-04-21 Hisamitsu Pharmaceutical Co., Inc. Rotigotine stabilization method
CN112891324A (zh) * 2021-01-19 2021-06-04 北京亚宝生物药业有限公司 一种透皮贴剂
CN116829131B (zh) * 2022-01-12 2024-05-07 新领医药技术(深圳)有限公司 奥氮平透皮给药系统及其制备方法和用途
CN117157062A (zh) * 2022-01-12 2023-12-01 新领医药技术(深圳)有限公司 抑制药物结晶的透皮贴剂及其制备方法
WO2024040860A1 (zh) * 2022-08-24 2024-02-29 新领医药技术(深圳)有限公司 抑制结晶的罗替高汀透皮给药系统及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3910543A1 (de) 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung
IT1243745B (it) 1990-10-17 1994-06-21 Vectorpharma Int Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
WO1997020550A2 (en) 1995-12-01 1997-06-12 Alza Corporation Improved method for preventing crystal formation in a dispersion of a liquid in a matrix
US5663258A (en) * 1996-02-20 1997-09-02 Isp Investments Inc. Strongly swellable, moderately crosslinked copolymers of vinylpyrrolidone and vinyl acetate
JPH1045571A (ja) * 1996-07-29 1998-02-17 Sekisui Chem Co Ltd 貼付剤
JPH10306023A (ja) 1997-05-06 1998-11-17 Sekisui Chem Co Ltd 経皮吸収製剤及びその製造方法
CA2302411C (en) * 1997-09-02 2007-01-30 Novartis Ag Improved method for preventing crystal formation in a scopolamine transdermal device
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
AR022471A1 (es) 1999-02-02 2002-09-04 Ortho Mcneil Pharm Inc Metodo para la fabricacion de matrices transdermicas
IL147247A0 (en) 1999-07-02 2002-08-14 Lohmann Therapie Syst Lts Microreservoir system based on polysiloxanes and ambiphilic solvents
DE10012908B4 (de) 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
US6824874B1 (en) * 2000-08-23 2004-11-30 Dana Corporation Insulator and seal for fuel cell assemblies
EP1386605A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE102006026578B4 (de) * 2006-06-08 2009-01-08 Lts Lohmann Therapie-Systeme Ag Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung
DE102006054732B4 (de) * 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
CN102281873A (zh) * 2008-10-06 2011-12-14 迈兰技术有限公司 非晶罗替戈汀（rotigotine）透皮系统
DE102009052972A1 (de) * 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
HUE039447T2 (hu) 2009-12-22 2018-12-28 Ucb Biopharma Sprl Polivinilpirrolidon rotigotin nem kristályos formája szilárd diszperziójának stabilizálására
JP5766475B2 (ja) * 2010-03-30 2015-08-19 日東電工株式会社 貼付製剤およびその製造方法
MY185130A (en) * 2010-07-12 2021-04-30 Celgene Corp Romidepsin solid forms and uses thereof

Also Published As

Publication number Publication date
BR112014016176A8 (pt) 2017-07-04
DE102011090178A1 (de) 2013-07-04
EP2797588B1 (de) 2016-04-27
JP2015503541A (ja) 2015-02-02
US20190328680A1 (en) 2019-10-31
EP2797588A1 (de) 2014-11-05
HK1202430A1 (zh) 2015-10-02
WO2013098390A1 (de) 2013-07-04
JP6335790B2 (ja) 2018-05-30
BR112014016176A2 (pt) 2017-06-13
CA2861782A1 (en) 2013-07-04
US20140378917A1 (en) 2014-12-25
CN110251490A (zh) 2019-09-20
CN104144683A (zh) 2014-11-12
BR112014016176B1 (pt) 2022-01-04
CA2861782C (en) 2020-04-14

Similar Documents

Publication Publication Date Title
ES2570205T3 (es) Sistema terapéutico transdérmico con pequeña tendencia a la cristalización espontánea
CL2007002485A1 (es) Proceso para preparar una forma de dosificacion farmaceutica oral solida de leberacion extendida que comprende un agente aactivo y oxido de polietileno de peso molecular de al menos 1.000.000, que incluye un paso de curado sometiendola a la temperatura de reblandecimiento o fusion (al menos parcial) del oxido de polietileno.
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
AR067309A1 (es) Formulaciones farmaceuticas que contienen derivados de acido lipoico
PE20151592A1 (es) Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
PE20160606A1 (es) Formas de dosificacion granuladas disuasivas del abuso de liberacion inmediata
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
DOP2010000390A (es) Compuestos de piridina
BRPI0606883A2 (pt) composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
EP2589379A4 (en) TRANSDERMAL AGGREGATE FREEZING SYSTEM WITH DONEPEZIL
BR112018010234A2 (pt) spray formador de película tópica
CY1116638T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
MX2015008286A (es) Composiciones multipolimericas para liberación transdermica de farmaco.
ECSP14010605A (es) Sistema para la administración de fármacos
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
CL2013002700A1 (es) Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros
UY33003A (es) Asociaciones farmacéuticas, composiciones farmacéuticas, medicamento y método para el tratamiento de animales
WO2014188329A3 (en) Transdermal extended dosing of pramipexole for neurological disorders
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
MY166972A (en) Transdermal delivery system containing galantamine or salts thereof
BR112014032264A8 (pt) Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
AR075058A1 (es) Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacion